Progenics Pharmaceuticals, Inc. and Cytogen Corporation have announced new findings on immune therapies which may play a future role in the treatment of prostate and other cancers. The therapies are directed against Prostate Specific Membrane Antigen (PSMA), a molecular cancer marker that is abundantly expressed on the surface of prostate cancer cells. The developments, presented Read more about Progenics And Cytogen Announce Progress On Vaccine And Antibody Therapies For Prostate Cancer[…]